Cocrystal Pharma (COCP) Stock Price

Cocrystal Pharma Price

NASDAQ·CLOSED
1.07
​
Market closed

Revenue at Cocrystal Pharma has contracted by 8.1% per year over the past 10 years to 5.43 M USD. Cocrystal Pharma's net margin stands at -261.4%, up from -1,100.0% several years earlier. Analysts set a median price target of 4.08 USD, implying 281.3% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Cocrystal Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cocrystal Pharma business model & stock analysis

Cocrystal Pharma Inc, based in Bothell, Washington, is a biotechnology company focused on developing novel antiviral therapeutics. The company specializes in discovering and commercializing treatments for serious viral diseases, including hepatitis C, influenza, and norovirus, using computational methods to design drug candidates. Listed on 12 March 2018, it currently employs 10 full-time staff.

Frequently asked questions about Cocrystal Pharma

Analysts currently set an average price target of 4.16 USD for the Cocrystal Pharma stock (median: 4.08 USD), implying +289.2 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Cocrystal Pharma stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Cocrystal Pharma share trades at 0.96 EUR (1.07 USD).

The Cocrystal Pharma share (COCP) is listed on 4 stock exchanges, including: NASDAQ (COCP), Frankfurt (8CC1.F), München (8CC1.MU), Düsseldorf (8CC1.DU).

The revenue cannot currently be calculated for Cocrystal Pharma.

The expected profit of Cocrystal Pharma is -6.90 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cocrystal Pharma is currently -1.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cocrystal Pharma stock.

The P/S cannot be calculated for Cocrystal Pharma currently.

The Eulerpool Quality Score for Cocrystal Pharma is 1/10.

The ISIN of Cocrystal Pharma is US19188J4094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Cocrystal Pharma is A2JCEJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Cocrystal Pharma is COCP. The ticker symbol is used to trade Cocrystal Pharma shares on the stock exchange.

Fair ValueTerminal
0.91 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 12, 2018
ISIN
US19188J4094
Cusip
19188J300
Sedol
BF5DYS4
Market capitalization
10.70 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.75
P/Ee 2027
-2.08
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.69
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-112.70 %
Last updated Nov 4, 2026, 9:33 AM

Cocrystal Pharma Ticker

DÜSSELDORF · 8CC1.DUFRANKFURT · 8CC1.FMUNICH · 8CC1.MUNASDAQ · COCP